Because regulations and internal policies evolve, MSLs should maintain regular communication with medical, legal, regulatory, and compliance colleagues. A best practice is to incorporate compliance review into the planning process early, rather than treating it as a final approval step.

Distinguishing Medical Education, Scientific Exchange, and Promotion

One of the most important compliance competencies for MSLs is the ability to distinguish between non-promotional scientific exchange and promotional communication. The distinction may appear subtle, but it has significant regulatory implications.

Scientific exchange is typically characterized by balanced, evidence-based discussion of scientific or medical information. It may include discussion of disease state, mechanism of action, clinical trial design, emerging data, safety considerations, unmet needs, and limitations of available evidence. It is generally reactive when addressing off-label questions and must be conducted by appropriately trained personnel.

Promotional communication, by contrast, is designed to influence prescribing or product use. It must remain consistent with approved labeling and be reviewed through promotional review processes. Promotional claims must be substantiated, fair-balanced, and compliant with applicable advertising and labeling regulations.

For MSLs, practical safeguards include:

• Avoiding sales-oriented language or statements that imply superiority without adequate evidence.
• Providing balanced context, including limitations of studies and safety information.
• Clearly documenting unsolicited requests when off-label information is discussed.
• Using approved medical materials and ensuring that all content has undergone the appropriate review.
• Maintaining separation from commercial objectives, targeting plans, and prescribing influence.

A helpful principle is that MSL engagements should be driven by scientific need, clinical relevance, and legitimate medical objectives rather than by commercial goals.

Balancing Scientific Exchange with Compliance: 5 Best Practices

1. Develop Clear Internal Protocols

Clear internal protocols are essential for planning and executing compliant educational activities. MSLs often operate in dynamic settings where questions arise in real time, including congresses, advisory boards, virtual programs, and one-on-one scientific discussions. A well-designed protocol helps ensure consistency, reduce risk, and support appropriate decision-making.

An internal compliance checklist should address:

• Confirmation of the educational objective and intended audience.
• Verification that content is scientifically accurate, balanced, and aligned with approved medical strategy.
• Identification of whether the activity is promotional, non-promotional, accredited CME, independent medical education, or scientific exchange.
• Review and approval requirements involving medical, legal, regulatory, and compliance teams.
• Documentation of HCP roles, qualifications, fair market value assessments, and contracts when applicable.
• Conflict-of-interest disclosures for faculty, authors, consultants, or advisors.
• Processes for capturing, documenting, and responding to unsolicited medical information requests.
• Retention of records, attendance logs, slide decks, correspondence, and post-activity summaries.

For higher-risk activities, such as advisory boards, product-related educational meetings, or programs involving external faculty, a pre-event compliance briefing is valuable. This allows the team to align on objectives, permissible discussion areas, escalation procedures, and documentation expectations before the activity begins.

2. Enhance Skills in Scientific Communication

Effective scientific communication is a core competency for MSLs. However, compliant communication requires more than technical accuracy. MSLs must communicate complex evidence in a way that is clear, balanced, and appropriately contextualized.

Best practices include presenting data with scientific rigor and avoiding overstatement. For example, when discussing clinical trial results, MSLs should address the study design, population, endpoints, statistical considerations, clinical relevance, safety findings, limitations, and generalizability. A statistically significant result should not automatically be framed as clinically meaningful unless the clinical context supports that interpretation.

MSLs should also avoid selective presentation of favorable data. Balanced communication includes acknowledging uncertainty, conflicting evidence, study limitations, and known safety concerns. This is particularly important when discussing emerging data, real-world evidence, subgroup analyses, or early-phase studies.

Effective techniques include:

• Using peer-reviewed evidence and approved medical materials whenever possible.
• Clearly distinguishing between established evidence and investigational or hypothesis-generating information.
• Avoiding promotional adjectives such as “best,” “breakthrough,” “game-changing,” or “preferred” unless these terms are supported by approved labeling or authoritative guidelines and permitted by policy.
• Responding directly to the question asked, particularly for unsolicited off-label inquiries.
• Checking for understanding and encouraging scientific dialogue rather than delivering one-way messaging.

A strong MSL does not simply present data; they help HCPs interpret evidence responsibly within the boundaries of compliance.

3. Manage Off-Label Discussions Appropriately

Off-label questions are common in scientific exchange, especially in therapeutic areas with rapid innovation, complex patient populations, or evolving standards of care. MSLs must be prepared to manage these discussions compliantly.

The key principle is that off-label information may generally be provided in response to a bona fide unsolicited request from an HCP, in a truthful, non-misleading, balanced, and scientifically rigorous manner, consistent with company policy and applicable regulations. MSLs should not proactively introduce off-label topics or use medical education as a vehicle to promote unapproved uses.

When handling an unsolicited off-label question, MSLs should:

• Clarify the question to ensure the response is appropriately tailored.
• Document the unsolicited nature of the request according to company procedure.
• Use approved medical response documents or appropriately reviewed scientific materials.
• Provide balanced information, including safety data, study limitations, and regulatory status.
• Avoid extrapolating beyond the available evidence.
• Refer to Medical Information or internal subject matter experts when needed.

For example, if an HCP asks about an investigational use of an approved therapy in a different patient population, the MSL should avoid making treatment recommendations. Instead, the MSL can summarize available data, clarify that the use is not approved, discuss limitations of the evidence, and direct the HCP to relevant publications or clinical trial information as appropriate.

4. Foster Compliant Collaborations with Key Opinion Leaders

Engagement with KOLs is a valuable component of medical education and scientific strategy. KOLs contribute clinical insights, identify unmet needs, advise on evidence generation, participate in advisory boards, and support peer-to-peer education when appropriate. However, KOL interactions are also subject to significant compliance scrutiny, particularly when compensation, influence, or product discussion is involved.

To ensure compliant collaboration, MSLs should clearly define the legitimate business or scientific need for the engagement. KOL selection should be based on objective criteria such as expertise, publication history, clinical experience, research involvement, or relevance to the scientific question—not prescribing volume or commercial potential.

Best practices include:

• Establishing a clear purpose and agenda for the engagement.
• Using written agreements that define scope of work, deliverables, time commitment, compensation, and confidentiality expectations.
• Ensuring compensation is consistent with fair market value and not tied to prescribing behavior or product use.
• Requiring disclosure of conflicts of interest where appropriate.
• Documenting the scientific insights generated and how they may inform medical strategy.
• Avoiding undue influence over faculty content in independent educational settings.

For advisory boards, MSLs should ensure that the discussion is genuinely consultative and not structured as a promotional presentation. The agenda should allow meaningful expert input, and outputs should be captured in a compliant manner. If slides are used, they should be reviewed through the appropriate medical and compliance process.

5. Maintain Appropriate Separation from Commercial Activities

MSLs often work cross-functionally with commercial colleagues, but their role must remain scientifically independent. Maintaining appropriate separation protects the integrity of medical affairs and reduces the risk that MSL activity is perceived as promotional.

MSLs should avoid activities that could be interpreted as sales support, such as delivering promotional messages, targeting HCPs based on prescribing behavior, collecting competitive intelligence for commercial advantage, or participating in discussions focused on increasing product utilization.

Appropriate cross-functional collaboration may include sharing aggregated medical insights, identifying educational gaps, informing evidence-generation strategy, or aligning on disease-state priorities. However, such collaboration should be governed by clear policies and should preserve the non-promotional nature of the MSL function.

A useful compliance test is to ask: “Is this activity being conducted to advance scientific understanding and patient care, or could it be perceived as influencing prescribing behavior?” If the answer is unclear, MSLs should seek guidance from compliance or legal colleagues before proceeding.

Compliance Considerations for Common Medical Education Activities

Independent Medical Education and CME

Independent medical education, including accredited CME, requires strict separation from commercial influence. When a company provides educational grants, the grant must not control content, faculty selection, or educational outcomes. The educational provider is responsible for ensuring independence, balance, and compliance with accreditation standards.

MSLs may identify legitimate educational gaps or communicate scientific needs through appropriate channels, but they should avoid directing the content of independent CME programs. Any involvement should align with internal policy and accreditation requirements.

Advisory Boards

Advisory boards should be designed to obtain genuine expert input on a defined scientific or medical question. They should not be used as promotional events or as a means to reward or influence HCPs.

Key safeguards include a documented rationale, appropriate participant selection, fair market value compensation, structured discussion guides, and clear documentation of insights. The number of participants should be reasonable for the objectives, and repeat engagements should be justified by a legitimate need.

Speaker Programs and Educational Presentations

Speaker programs require careful governance because they can be perceived as promotional if not structured appropriately. Content, audience selection, speaker training, compensation, and venue selection must all be consistent with applicable laws and company policy.

MSLs involved in non-promotional educational presentations should ensure that content is medically accurate, balanced, and reviewed through the appropriate process. If the activity is promotional, it should be managed under promotional rules and delivered by personnel authorized for that purpose.

Congresses and Scientific Meetings

Congresses create opportunities for scientific exchange, data dissemination, and stakeholder engagement. They also present compliance risks, particularly around booth interactions, unsolicited questions, social media activity, and discussions of investigational data.

MSLs should be trained on congress-specific guidance, including how to respond to off-label questions, how to document interactions, and what materials may be shared. Scientific exchange should remain aligned with the setting and the role of the MSL.

Monitoring Digital Compliance Risks

Medical education increasingly occurs through webinars, virtual advisory boards, online congress platforms, podcasts, digital portals, and social media. These channels expand reach and engagement but also introduce unique compliance challenges.

Potential risks include misinterpretation of digital content, inappropriate sharing beyond the intended audience, data privacy concerns, inadequate documentation, and the blending of educational and promotional messaging. Digital formats may also create challenges around audience verification, consent management, and cross-border access.

MSLs and medical affairs teams should proactively establish digital governance processes, including:

• Review and approval of digital content before dissemination.
• Clear labeling of content as medical, educational, promotional, or investigational where appropriate.
• Audience controls to ensure materials reach the intended HCP or scientific audience.
• Data privacy safeguards consistent with applicable requirements such as HIPAA, GDPR, and local privacy laws.
• Monitoring procedures for chat functions, Q&A, comments, and social media interactions.
• Documentation of questions, responses, attendance, and follow-up actions.

For live virtual meetings, moderators should be prepared to manage off-label questions, redirect inappropriate discussion, and ensure that responses are handled by qualified personnel. For on-demand content, teams should consider whether content may become outdated and establish review cycles or expiration dates.

Real-World Example: Managing an Unsolicited Off-Label Question During a Virtual Advisory Board

Consider a virtual advisory board convened to discuss unmet needs in a chronic inflammatory disease. During the discussion, an HCP asks whether the company’s approved therapy has been studied in a related but unapproved indication.

A compliant MSL response would involve acknowledging the question, confirming that the requested use is not approved, and providing only information that is responsive to the unsolicited inquiry. The MSL may reference available peer-reviewed data or direct the HCP to Medical Information for a formal response. The exchange should be documented according to company policy.

A non-compliant response would involve proactively expanding the discussion into unapproved treatment positioning, suggesting clinical use, comparing the investigational use favorably against approved alternatives, or encouraging other participants to consider the off-label application.

This example illustrates an important principle: the compliance risk often lies not in the question itself, but in how the response is framed, documented, and followed up.

Documentation: The Foundation of Defensible Medical Education

Accurate documentation is one of the most important safeguards in medical education. If an activity is later reviewed by internal auditors, regulators, or compliance teams, documentation provides evidence of intent, process, and adherence to policy.

MSLs should document:

• The objective and rationale for the educational activity.
• The audience, faculty, and participant selection criteria.
• Approval records for content and materials.
• Contracts, disclosures, and fair market value assessments.
• Unsolicited requests and responses, when applicable.
• Medical insights gathered during scientific exchange.
• Deviations, incidents, corrective actions, and follow-up steps.

Documentation should be factual, timely, and objective. It should avoid subjective comments about prescribing potential, commercial opportunity, or HCP influence. When documenting insights, MSLs should focus on scientific themes, clinical barriers, data gaps, and patient care considerations.

Building a Culture of Compliance in Medical Affairs

Compliance is most effective when it is embedded into the culture of medical affairs rather than treated as an administrative burden. MSL leaders can reinforce this culture by encouraging proactive consultation, scenario-based training, and open discussion of challenging situations.

Effective compliance training for MSLs should go beyond policy review. It should include realistic role-play scenarios, examples of compliant and non-compliant language, guidance on digital engagement, and practical decision frameworks for high-risk interactions. MSLs should also feel empowered to pause an activity or escalate a concern when appropriate.

A strong compliance culture supports scientific credibility. HCPs are more likely to trust MSLs who provide balanced information, acknowledge uncertainty, and operate with transparency.

Conclusion

Navigating compliance in medical education presents both challenges and opportunities for MSLs. By establishing clear protocols, strengthening scientific communication, managing off-label discussions appropriately, collaborating with KOLs transparently, and maintaining separation from commercial activity, MSLs can deliver educational initiatives that are both compliant and impactful.

The regulatory environment will continue to evolve alongside advances in science, digital communication, and healthcare delivery. For medical affairs professionals, ongoing education, cross-functional collaboration, and disciplined documentation are essential to maintaining trust and ensuring that medical education supports evidence-based patient care.

What strategies will your team implement to enhance compliance during educational initiatives? With continued regulatory scrutiny and rapid technological change, proactive preparation is no longer optional—it is central to effective medical affairs practice.

For practitioners looking to enhance their knowledge and skills in medical affairs, consider the Board Certified Medical Affairs Specialist (BCMAS) certification. This program provides comprehensive training, aligning with industry standards to enhance practitioner competencies.

FAQs

Q1: What are the potential implications of non-compliance in medical education?
Non-compliance can result in regulatory enforcement, financial penalties, reputational damage, corrective action plans, exclusion risks, and loss of trust among HCPs, patients, and internal stakeholders. It may also compromise the perceived integrity of scientific exchange and medical education.

Q2: How can MSLs ensure that their presentations remain compliant while still being effective?
MSLs can remain compliant by using approved medical materials, presenting balanced and evidence-based data, avoiding promotional language, acknowledging study limitations, and ensuring that any off-label discussion is handled only in response to a bona fide unsolicited request. Effective communication does not require promotional framing; it requires clarity, relevance, scientific rigor, and appropriate context.

Q3: What resources can MSLs refer to for compliance guidelines?
MSLs should refer to applicable FDA and EMA guidance, national regulations, the PhRMA Code, ACCME Standards for accredited education, internal company policies, medical information procedures, and compliance training materials. For publication-related activities, Good Publication Practice principles are also important.

Q4: How often should MSLs update their compliance knowledge?
MSLs should refresh compliance knowledge regularly and review key updates at least quarterly. Additional training should occur when new regulations are issued, company policies change, new digital engagement channels are introduced, or the MSL begins work in a new therapeutic area or geography.

Q5: What is the best way to handle a compliance challenge that arises during an educational initiative?
The MSL should address the situation promptly, avoid further escalation of the risk, document the incident objectively, and consult compliance, legal, or medical leadership according to company policy. If necessary, the team should implement corrective actions, update training, revise materials, or adjust future procedures.

Q6: Can MSLs discuss off-label information with HCPs?
MSLs may generally respond to unsolicited HCP questions about off-label information when permitted by company policy and applicable regulations. Responses should be truthful, balanced, non-misleading, scientifically supported, and appropriately documented. MSLs should not proactively promote off-label uses.

Q7: What makes KOL engagement compliant?
Compliant KOL engagement requires a legitimate scientific purpose, objective selection criteria, transparent contracting, fair market value compensation, conflict-of-interest disclosure, and appropriate documentation. KOLs should never be engaged as a reward for prescribing behavior or as a means to influence product use.

Q8: How should MSLs manage compliance in digital education?
MSLs should ensure that digital content is reviewed and approved, audience access is appropriate, privacy requirements are met, Q&A functions are monitored, and interactions are documented. Digital materials should also be reviewed periodically to ensure that scientific content remains current and accurate.

By focusing on these principles, MSLs can effectively balance meaningful scientific engagement with the rigorous compliance expectations that govern medical education. Done well, compliant medical education strengthens trust, advances scientific understanding, and supports better-informed clinical decision-making.